Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.
Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
These findings are an example of the power of genomic sequencing and bioinformatic analysis - with a…
Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System
Great work by Mike Overman and colleagues showing prolonged benefit to Nivo (3 mg,kg) and Ipi (1 mg,…
Director WVU Cancer Institute
Director of Cancer Signature Program
Laurence S. and Jean J. DeLynn Chair of Oncology
This is a very interesting study that opens the door to prospective investigation of a randomized tr…
Executive Director
Community Oncology Alliance
Very important analysis conducted by Dr. Lucio Gordan and fellow researchers. Shows the adverse impa…
National Health Policy Expert
C-VICER: CVS Embraces ICER
We have reached a v…
Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine
The results of OSPREY 2301 will need to be confirmed, but look quite promising and address one of th…
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)
Disappointing result, especially since treatment with either topotecan or amrubicin in relapsed SCLC…
President, W-Squared Group
From a payer perspective, I do not think the clinical utility of the liquid biopsy has been show to …
Managing Director and Senior Biotechnology Analyst
I am excited to be joining the editorial board on OBR; I have been a fan of the publication since it…
Chief Medical Officer and Founder, N-of-One
No comments to show!
Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA
This long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …
FACP FACPE FASCO
President, Minnesota Oncology
In contrast, chemotherapy initiation in the outpatient setting is being continually delayed due to p…
CEO
Tennessee Oncology
I found this article both fascinating and enlightening. I had not thought of "burnout" in terms of …
Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors
Thanks Lucio - good job. It is hard to believe that there is not a concerted effort to destroy commu…
Florida Cancer Specialists
President and Managing Partner
At Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it…
Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Interesting experience using focal radiation techniques (with injected radiation) to treat HCC. Ther…
